GB201915618D0 - ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases - Google Patents
ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseasesInfo
- Publication number
- GB201915618D0 GB201915618D0 GB201915618A GB201915618A GB201915618D0 GB 201915618 D0 GB201915618 D0 GB 201915618D0 GB 201915618 A GB201915618 A GB 201915618A GB 201915618 A GB201915618 A GB 201915618A GB 201915618 D0 GB201915618 D0 GB 201915618D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- alk
- antibody
- treatment
- mediated diseases
- negative cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201915618A GB201915618D0 (en) | 2019-10-28 | 2019-10-28 | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
| CA3159339A CA3159339A1 (en) | 2019-10-28 | 2020-03-12 | Alk inhibitors for treatment of alk-negative cancer and plasma cell-mediated diseases |
| PCT/EP2020/056698 WO2021083555A1 (en) | 2019-10-28 | 2020-03-12 | Alk inhibitors for treatment of alk-negative cancer and plasma cell-mediated diseases |
| EP20711156.8A EP4051288A1 (en) | 2019-10-28 | 2020-03-12 | Alk inhibitors for treatment of alk-negative cancer and plasma cell-mediated diseases |
| CN202080089754.2A CN114901289A (zh) | 2019-10-28 | 2020-03-12 | 用于治疗alk阴性癌症和浆细胞介导的疾病的alk抑制剂 |
| KR1020227018050A KR102946955B1 (ko) | 2019-10-28 | 2020-03-12 | Alk-음성 암 및 형질 세포-매개 질환의 치료를 위한 alk 억제제 |
| US17/772,192 US12465607B2 (en) | 2019-10-28 | 2020-03-12 | ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases |
| AU2020374150A AU2020374150B2 (en) | 2019-10-28 | 2020-03-12 | ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases |
| JP2022525050A JP7629228B2 (ja) | 2019-10-28 | 2020-03-12 | Ａｌｋ陰性癌および形質細胞媒介性疾患の治療のためのａｌｋ阻害剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201915618A GB201915618D0 (en) | 2019-10-28 | 2019-10-28 | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201915618D0 true GB201915618D0 (en) | 2019-12-11 |
Family
ID=68768829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB201915618A Ceased GB201915618D0 (en) | 2019-10-28 | 2019-10-28 | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12465607B2 (https=) |
| EP (1) | EP4051288A1 (https=) |
| JP (1) | JP7629228B2 (https=) |
| KR (1) | KR102946955B1 (https=) |
| CN (1) | CN114901289A (https=) |
| AU (1) | AU2020374150B2 (https=) |
| CA (1) | CA3159339A1 (https=) |
| GB (1) | GB201915618D0 (https=) |
| WO (1) | WO2021083555A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230091284A (ko) * | 2021-12-16 | 2023-06-23 | 부산대학교 산학협력단 | Surf4 억제제를 포함하는 혈액암의 예방 또는 치료용 약학적 조성물 |
| WO2024017334A1 (zh) * | 2022-07-22 | 2024-01-25 | 贝达药业股份有限公司 | 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒 |
| CN115993453B (zh) * | 2022-07-22 | 2025-03-25 | 四川大学 | 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒 |
| WO2024059525A2 (en) * | 2022-09-12 | 2024-03-21 | Endotarget, Inc. | Compounds and methods for the targeted degradation of anaplastic lymphoma kinase and ros1 kinase |
| KR20250160958A (ko) * | 2023-03-22 | 2025-11-14 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | 약학적 조합 및 이의 응용 |
| CN119700981A (zh) * | 2024-12-24 | 2025-03-28 | 中南大学湘雅二医院 | Alk/ltk抑制剂在制备治疗和/或预防慢性淋巴细胞白血病的产品中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017405B9 (ru) | 2006-12-08 | 2014-05-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| AU2009233963B2 (en) | 2008-04-07 | 2011-10-06 | Irm Llc | Compounds and compositions as kinase inhibitors |
| US8904383B2 (en) | 2008-04-10 | 2014-12-02 | Hewlett-Packard Development Company, L.P. | Virtual machine migration according to environmental data |
| PE20100087A1 (es) | 2008-06-25 | 2010-02-08 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
| BR112013015000A2 (pt) | 2010-12-17 | 2016-08-09 | Novartis Ag | formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina |
| EP2916841A1 (en) | 2012-11-07 | 2015-09-16 | Novartis AG | Combination therapy |
| US10117872B2 (en) | 2014-03-28 | 2018-11-06 | Università Degli Studi Di Genova | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake |
| CN105294649B (zh) | 2014-07-30 | 2019-05-14 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| US10695426B2 (en) * | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| KR20170060042A (ko) * | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| CN105622577A (zh) * | 2014-11-29 | 2016-06-01 | 江苏先声药业有限公司 | 一种色瑞替尼的新晶型及其制备方法 |
| WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
| WO2016098042A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders |
| JP2018529719A (ja) * | 2015-09-30 | 2018-10-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ |
| JPWO2019039390A1 (ja) | 2017-08-25 | 2020-07-30 | 国立大学法人東海国立大学機構 | 若年性骨髄単球性白血病治療薬 |
| WO2019113345A1 (en) | 2017-12-06 | 2019-06-13 | Spyro Mousses | Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases |
| CN110063956A (zh) * | 2018-01-20 | 2019-07-30 | 中国科学院上海药物研究所 | 治疗肝癌的药物组合和方法 |
-
2019
- 2019-10-28 GB GB201915618A patent/GB201915618D0/en not_active Ceased
-
2020
- 2020-03-12 CA CA3159339A patent/CA3159339A1/en active Pending
- 2020-03-12 JP JP2022525050A patent/JP7629228B2/ja active Active
- 2020-03-12 AU AU2020374150A patent/AU2020374150B2/en active Active
- 2020-03-12 US US17/772,192 patent/US12465607B2/en active Active
- 2020-03-12 KR KR1020227018050A patent/KR102946955B1/ko active Active
- 2020-03-12 WO PCT/EP2020/056698 patent/WO2021083555A1/en not_active Ceased
- 2020-03-12 EP EP20711156.8A patent/EP4051288A1/en active Pending
- 2020-03-12 CN CN202080089754.2A patent/CN114901289A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102946955B1 (ko) | 2026-04-02 |
| CA3159339A1 (en) | 2021-05-06 |
| JP2022554258A (ja) | 2022-12-28 |
| WO2021083555A1 (en) | 2021-05-06 |
| EP4051288A1 (en) | 2022-09-07 |
| CN114901289A (zh) | 2022-08-12 |
| US20220401444A1 (en) | 2022-12-22 |
| AU2020374150B2 (en) | 2025-12-18 |
| JP7629228B2 (ja) | 2025-02-13 |
| US12465607B2 (en) | 2025-11-11 |
| KR20220098158A (ko) | 2022-07-11 |
| AU2020374150A1 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201915618D0 (en) | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases | |
| IL288522A (en) | Inhibitor of egfr for cancer treatment | |
| IL284324A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL284326A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL308195A (en) | RAS inhibitors for cancer treatment | |
| IL277665A (en) | Heterocyclic inhibitors of MAT2A and methods of use for cancer therapy | |
| IL288395A (en) | Mat2a tricyclic inhibitors and methods for use in cancer therapy | |
| SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
| EP4010081A4 (en) | POLYTHERAPY FOR THE TREATMENT OF CANCER | |
| EP3856352A4 (en) | Methods of treatment of cancer comprising cdc7 inhibitors | |
| IL316829A (en) | Menin-MLL inhibitors for cancer treatment | |
| IL285050A (en) | Administering PD-1 inhibitors for the treatment of skin cancer | |
| IL288787A (en) | Methods and preparations to improve results in cancer patients | |
| IL290373A (en) | Combinations of tgfb inhibitors and cdk inhibitors for the treatment of breast cancer | |
| EP3758678A4 (en) | METHODS OF TREATMENT OF CANCER WITH CHK1 INHIBITORS | |
| IL283885A (en) | cxcr7 inhibitors for cancer therapy | |
| EP3989985A4 (en) | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC CANCER | |
| IL287538A (en) | Preparations and methods for the treatment of cancer | |
| IL305780A (en) | Cancer treatment methods | |
| IL288003A (en) | Cancer treatment methods using chk1 inhibitors | |
| EP4051260A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| ES3063341T3 (en) | Cyp2e1 inhibitors for the treatment of inflammatory-mediated diseases | |
| IL288433A (en) | Peroxidase-3 activation and immunotherapy for cancer treatment | |
| GB201918815D0 (en) | Treatment of cancer | |
| EP3760614B8 (en) | Chemical inhibitors of id proteins for the treatment of cancer and other diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |